To the Editor:Non-Hodgkin lymphoma(NHL)is a common type of hematological malignancy.Although the development of targeted therapies has improved the survival of patients with aggressive NHL,autologous hematopoietic ste...To the Editor:Non-Hodgkin lymphoma(NHL)is a common type of hematological malignancy.Although the development of targeted therapies has improved the survival of patients with aggressive NHL,autologous hematopoietic stem cell transplantation(HSCT)remains indispensable.There is no standard conditioning regimen for autologous stem cell transplantation(ASCT).展开更多
基金National Natural Science Foundation of China(Nos.81770166,81700193,82170186 and 81720108002)Jiangsu Province’s Medical Elite Programme(No.ZDRCA2016022)+4 种基金Project of National Key Clinical Specialty,Jiangsu Provincial Special Program of Medical Science(No.BE2017751)National Science and Technology Major Project(No.2018 ZX09734007)China Postdoctoral Science Foundation(No.2021M691336)Jiangsu Postdoctoral Science Foundation(No.2021K083A)Translational Research Grant of NCRCH(No.2020ZKZB01)
文摘To the Editor:Non-Hodgkin lymphoma(NHL)is a common type of hematological malignancy.Although the development of targeted therapies has improved the survival of patients with aggressive NHL,autologous hematopoietic stem cell transplantation(HSCT)remains indispensable.There is no standard conditioning regimen for autologous stem cell transplantation(ASCT).
